CTLA4 and cancer: Treatment of patients using immune checkpoint inhibitors, such as antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1 (PD-1) and programmed death-ligand 1 (PD-L1) that enhance T cell-mediated immune responses against cancer, is considered a major breakthrough1,2.